
Susana Banerjee/wikipedia.org
Jul 13, 2025, 11:56
Susana Banerjee: First Approved Therapy for Low Grade Serous Ovarian Cancer
Susana Banerjee, Professor in Women’s Cancers at The Institute of Cancer Research, shared on X:
“Phase 2 RAMP201 (ENGOTov60/GTG-UK/GOG3052) trial leading to FDA accelerated approval avumetinib and defactinib now published in Journal of Clinical Oncology, Verastem Oncology. First approved therapy for low grade serous ovarian cancer. Thanks all.”
Read this insightful article about Ovarian Cancer:
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 13, 2025, 11:56
Jul 13, 2025, 11:48
Jul 13, 2025, 11:38
Jul 13, 2025, 11:36
Jul 13, 2025, 11:36
Jul 13, 2025, 11:23
Jul 13, 2025, 10:26
Jul 13, 2025, 06:23